Background: Adiponectin plays an important role in glucose metabolism and released in response to insulin. It helps to decrease glucose levels and insulin resistance; however, this relation is not been studied in pregnant ladies. Objective was to determine serum adiponectin level and glycaemic status in pregnant women belonging to Peshawar, Khyber Pakhtunkhwa (KPK) and to find any possible relationship between them. Methods: Hundred pregnant women with gestational diabetes mellitus (GDM) and 100 healthy pregnant women without GDM were randomly selected in a cross-sectional study. After an overnight fast, their blood samples were taken for determination of serum adiponectin, glycosylated haemoglobin (HbA1c) and fasting blood glucose (FBG). The relationship of adiponectin with glycaemic status was determined with Pearson Correlations coefficient (r). Results: Pregnant women with GDM when compared to healthy pregnant women showed significantly low levels of serum adiponectin (µg/mL) (2.2±0.2 vs. 11.25±4.8, p<0.05) and significantly high level of FBG (mg/dl) (182.7±64.2 vs. 93.6±5.9, p<0.05) and HbA1c (%) (7.4±0.1 vs. 5.4±0.1, p<0.05). Serum adiponectin level showed a statistically significant negative correlation with FBG (r = -0.203, p=0.042) and HbA1c (r = -0.744, p=0.000) in pregnant women with GDM. Conclusion: Serum adiponectin concentration is markedly decreased in pregnant women with GDM which concludes that Hypoadiponectinemia is related with deranged (elevated) glycaemic status in pregnancy. Moreover, adiponectin is associated negatively with FBG and HbA1c in the studied population.
An eighteen-year-old pregnant woman presented with history of acute loss of vision in the right eye for 4 days. Clinical examination revealed central retinal artery occlusion in the right eye. All investigations were normal except MRI brain. MRI report suggested the possibility of acute vasculitis or Susac syndrome; it should be considered in all cases of acute retinal artery occlusions occurring in apparently healthy young females without any precipitating factors. The syndrome may not manifest with full clinical triad.
Objective: This trial was conducted to evaluate the effectiveness of oral hypoglycemic agents on diabetic control and biochemical parameters of known diabetic subjects. Introduction: T2DM occurs due to abnormal metabolism of carbohydrate, proteins and lipids leading to increased blood glucose characterized by polyuria and polydypsia due to relative 5deficiency or lack of insulin. Beside dietary control and insulin therapy, various oral hypoglycemic such as sulfonylurea biguanide, thiazolidinedione, DPP–4 inhibitors, glucagon–like peptide inhibitors and SGL2. Material and Methods: This comparative trial was carried out on previously diagnosed type–2 diabetic subjects. This trial was conducted at health care centers of District Nowshehra viz. NMC Nowshehra, DHQ Hospital Nowshehra, and ICS, Peshawar in collaboration with KMC and PIMC Peshawar, Khyber Pakhtunkhwa, Pakistan. A total of 200 known diabetic subjects were randomly recruited on the basis of predetermined selection criteria and were splited into two groups. Group A having 100 diabetic subjects was given DPP–4 inhibitor; Sitagliptin 50 mg two times a day alone for six (06) months while Group B comprising of 100 patients were treated with combination of DPP–4 inhibitor (Sitagliptin 50 mg 1BD) and Metformin in a dose of 500 mg two times a day. Venous blood samples were taken from each patient in both fasting (10–12 hour night long fast) and random (2 hour post prandial) state. FBS, RBS, HbA1C, S. creatinine and fasting S. lipid profile were determined by using spectrophotometric colorimetric methods using kits (procured from Elitech, Spain) at 03 and 06 months follow up. Inclusion criteria was subjects with T2DM of age 18 years and above. T2DM patients on insulin, diabetic nephropathy and retinopathy were excluded. The data was analyzed by using SPSS software version 20. Results: Significant results (p < 0.05) were seen for glycemic control (FBS, RBS, HbA1C) in Group B as compare to Group A patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.